Eikon Therapeutics, Inc.
$11.55
▼
-1.79%
2026-04-21 06:36:00
eikontx.com
NMS: EIKN
Explore Eikon Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$644.25 M
Current Price
$11.55
52W High / Low
$17.4 / $8.58
Stock P/E
—
Book Value
$-286.47
Dividend Yield
—
ROCE
-62.8%
ROE
-1.25%
Face Value
—
EPS
$-6.18
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
384
Beta
—
Debt / Equity
91.11
Current Ratio
6.34
Quick Ratio
6.34
Forward P/E
-1.59
Price / Sales
—
Enterprise Value
$1.57 B
EV / EBITDA
-5.31
EV / Revenue
—
Rating
Buy
Target Price
$25.6
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Polyrizon Ltd. | $11.64 | — | $20.34 M | — | -27.56% | -25.38% | $2,235 / $2.88 | $13.05 |
| 2. | Daré Bioscience, Inc. | $2.87 | — | $41.79 M | — | -154.2% | 845.53% | $9.19 / $1.27 | $0.2 |
| 3. | DiaMedica Therapeutics Inc. | $6.56 | — | $369.1 M | — | -61.16% | -67.68% | $10.42 / $3.28 | $1.04 |
| 4. | Immuneering Corporation | $5.53 | — | $359.47 M | — | -26.76% | -43.12% | $10.08 / $1.1 | $3.38 |
| 5. | Ardelyx, Inc. | $6.3 | — | $1.59 B | — | -9.92% | -36.21% | $8.4 / $3.21 | $0.68 |
| 6. | Arcturus Therapeutics Holdings Inc. | $8.9 | — | $251.54 M | — | -32.48% | -28.92% | $24.17 / $5.85 | $7.53 |
| 7. | X4 Pharmaceuticals, Inc. | $4.19 | — | $372.04 M | — | -32.82% | -75.99% | $6.63 / $1.35 | $2.05 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q4 2024 | |
|---|---|---|
| Sales | 0 M | 0 M |
| Operating Profit | -83.17 M | -67.78 M |
| Net Profit | -79.66 M | -64.92 M |
| EPS in Rs | -1.47 | -1.2 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Sales | 0 M | 0 M | 0 M |
| Operating Profit | -338.94 M | -260.34 M | -265.74 M |
| Net Profit | -324.25 M | -243.81 M | -242 M |
| EPS in Rs | -5.99 | -4.5 | -4.47 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Total Assets | 594.73 M | 491.24 M | 525.71 M |
| Total Liabilities | 1.47 B | 1.06 B | 867.08 M |
| Equity | -879.03 M | -571.93 M | -341.37 M |
| Current Assets | 348.92 M | 227.89 M | 436.43 M |
| Current Liabilities | 55.01 M | 56.45 M | 31.44 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating CF | -188.52 M | -134.8 M | -190.85 M |
| Investing CF | -181.34 M | 151.35 M | 136.95 M |
| Financing CF | 352.05 M | 0.24 M | 105.81 M |
| Free CF | -235.26 M | -219.6 M | -219.36 M |
| Capex | -46.74 M | -84.8 M | -28.51 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue Growth % | — | — | — |
| Earnings Growth % | -32.99% | -0.75% | — |
| Profit Margin % | — | — | — |
| Operating Margin % | — | — | — |
| Gross Margin % | — | — | — |
| EBITDA Margin % | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.